← Back to Search

Other

Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma

N/A
Waitlist Available
Led By Saroj Vadhan-Raj, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through 4 weeks of treatment
Awards & highlights
No Placebo-Only Group

Summary

Primary Objectives: 1. To evaluate clinical tolerance and response to curcumin alone and in combination with Bioperine in patients with multiple myeloma. 2. To compare the pharmacokinetics and pharmacodynamics of curcumin and curcumin + Bioperine and evaluate the effect of Bioperine on the bioavailability of curcumin. 3. To evaluate the biologic effects of curcumin alone and in combination with Bioperine on the expression of NF-kB and related genes in the Multiple Myeloma (MM) cells.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through 4 weeks of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through 4 weeks of treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percent Change of NF-kB Protein Expression in Peripheral Blood Mononuclear Cells From Baseline Through 4 Weeks of Treatment

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Curcumin + BioperineExperimental Treatment2 Interventions
Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.) and Bioperine 5 mg orally twice daily.
Group II: CurcuminExperimental Treatment1 Intervention
Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Curcumin
FDA approved
Piperine
Not yet FDA approved

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,074 Previous Clinical Trials
1,803,503 Total Patients Enrolled
85 Trials studying Multiple Myeloma
6,571 Patients Enrolled for Multiple Myeloma
Saroj Vadhan-Raj, MDPrincipal InvestigatorMDAnderson Cancer Center
12 Previous Clinical Trials
519 Total Patients Enrolled
~2 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top